Cardiac Arrhythmias: New Therapeutic Drugs and Devices: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984 / Edition 1

Hardcover (Print)
Buy New
Buy New from
Used and New from Other Sellers
Used and New from Other Sellers
from $128.25
Usually ships in 1-2 business days
(Save 59%)
Other sellers (Hardcover)
  • All (5) from $128.25   
  • New (4) from $283.70   
  • Used (1) from $128.25   

Product Details

  • ISBN-13: 9780898387162
  • Publisher: Springer US
  • Publication date: 4/30/1985
  • Series: Developments in Cardiovascular Medicine Series, #47
  • Edition description: 1985
  • Edition number: 1
  • Pages: 356
  • Product dimensions: 9.21 (w) x 6.14 (h) x 0.88 (d)

Table of Contents

I Basic Considerations.- 1 What animal models are useful in selecting new antiarrhythmic drugs?.- 2 How to test for antiarrhythmic drugs.- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?.- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?.- Panel Discussion: Basic considerations.- II Status of Specific Antiarrhythmic Agents.- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — efficacy in the treatment of ventricular arrhythmias: current status and controversies.- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents.- 7 Class IC antiarrhythmic agents: status — 1984.- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias.- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol.- Panel Discussion: Status of specific antiarrhythmic agents.- III Special Considerations and FDA Standards.- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice.- 11 Use of a computer in the new drug evaluation process.- 12 Sudden cardiac death — failure or effect of antiarrhythmic drug therapy?.- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs.- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?.- Panel Discussion: Special considerations and FDA standards.- IV New Antiarrhythmic Devices.- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?.- 16 Pacing for ventricular tachycardia.- 17 Termination of ventricular tachycardia by transvenous cardioversion.- 18 The automatic implantable cardioverter/defibrillator.- 19 New antiarrhythmia devices — FDA’s requirements for effectiveness.- Panel Discussion: New antiarrhythmic devices.- V Evaluation Of Atrial Arrhythmias.- 20 Study designs to evaluate atrial arrhythmias are easy.- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection.- 22 Approaches to drug selection and serial drug testing.- Panel Discussion: Evaluation of atrial arrhythmias.- Participants.
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Terms of Use.
  • - Barnes & reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)